OP32: The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivoECCO’23 CopenhagenYear: 2023
Authors: Facoetti, A.(1)*;Massimino, L.(2);Palmieri, O.(3);Fuggetta , D.(1);Spanò , S.(2);D'Alessio , S.(4);Furfaro, F.(5);D'Amico, F.(5);ZIlli, A.(5);Fiorino, G.(5);Noviello, D.(6);Latiano, A.(3);Bossa, F.(3);Pirola, A.(7);Mologni, L.(8);Piazza, R.(8);Abbati, D.(9);Perri, F.(3);Bonini , C.(9);Peyrin-Biroulet, L.(10);Malesci, A.(5);Danese, S.(5);Ungaro, F.(2);
(1)Università Vita-Salute San Raffaele, Department of Gastroenterology and Digestive Endoscopy in the Laboratory of Experimental Gastroenterology, Milan, Italy;(2)IRCCS Ospedale San Raffaele, Department of Gastroenterology and Digestive Endoscopy in the Laboratory of Experimental Gastroenterology, Milan, Italy;(3)Fondazione IRCCS Casa Sollievo della Sofferenza, Division of Gastroenterology, San Giovanni Rotondo FG, Italy;(4)Phoenix Lab, none, Lody, Italy;(5)IRCCS Ospedale San Raffaele, Department of Gastroenterology and Digestive Endcoscopy, Milan, Italy;(6)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;(7)Galseq, None, Milan, Italy;(8)University of Milano - Bicocca, Department of Medicine and Surgery, Monza, Italy;(9)IRCCS Ospedale San Raffaele, Division of Immunology- Transplantation and Infectious Disease, Milan, Italy;(10)Inserm NGERE, University of Lorraine, Nancy, France;
OP33: Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)ECCO’23 CopenhagenYear: 2023
Authors: Raine, T.(1)*;Vaja, S.(2);Subramanian, S.(1);Brezina, B.(1);Probert, C.S.(3);Steel, A.(3);Lofthouse, M.(3);Speight, R.A.(4);Lamb, C.(4);Sebastian, S.(5);Kane, J.(5);Thut, J.(5);Din, S.(6);Arnott, I.(6);Smith, L.(6);Galea, J.(7);Hendy, P.(8);Flores, L.(9);Selinger, C.(10);Onoviran, F.(10);Steed, H.(11);Green, M.(12);Williams, J.(13);Jairath, V.(14);Qian, W.(2);Pavey, H.(2);Champion, K.(2);Dowling, F.(2);Thomas, M.(2);Wolf, K.(2);Davis-Wilkie, C.(2);Parkes, M.(1);Kaser, A.(15);
(1)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;(2)Cambridge University Hospitals NHS Foundation Trust, Cambridge Clinical Trials Unit, Cambridge, United Kingdom;(3)Royal Liverpool University Hospital, Department of Gastroenterology, Liverpool, United Kingdom;(4)Royal Victoria Infirmary, Department of Gastroenterology, Newcastle, United Kingdom;(5)Hull University Teaching Hospitals, IBD Unit, Hull, United Kingdom;(6)Western General Hospital- NHS Lothian, IBD Unit, Edinburgh, United Kingdom;(7)Cardiff and Vale University Health Board- Cardiff, Neurosurgery, Cardiff, United Kingdom;(8)Chelsea and Westminster NHS Trust, Department of Gastroenterology, London, United Kingdom;(9)Chelsea and Westminster NHS Trust, Research and Development, London, United Kingdom;(10)St James University Hospital, Department of Gastroenterology, Leeds, United Kingdom;(11)University of Wolverhampton, Department of Gastroenterology, Wolverhampton, United Kingdom;(12)The Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(13)Swansea University, Department of Medicine, Swansea, United Kingdom;(14)Western University, Department of Gastroenterology, London, Canada;(15)University of Cambridge, Department of Medicine, Cambridge, United Kingdom;The IASO trial investigators
OP34: Enteral Nutrition Compared with Steroids in Children with Crohn's Disease – In Israel: a nationwide study from the epi-IIRNECCO’23 CopenhagenYear: 2023
Authors: Plotkin, L.(1)*;Lujan, R.(1);Focht, G.(1);Greenfeld, S.(2);Loewenberg Weisband, Y.(3);Lederman, N.(4);Matz, E.(5);Dotan, I.(6);Turner, D.(1);
(1)Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center- The Hebrew University of Jerusalem- Israel, Jerusalem, Israel;(2)Maccabi Health Services and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel;(3)Clalit Health Services, Clalit Research Institute- Tel-Aviv- Israel, Tel-Aviv, Israel;(4)Meuhedet Health Services, Meuhedet Health Services, Tel-Aviv, Israel;(5)Leumit Health Services, Leumit Health Services, Tel-Aviv, Israel;(6)Division of Gastroenterology- Rabin Medical Center- Petah Tikva, and the Sackler Faculty of Medicine- Tel Aviv University, Tel-Aviv, Israel;
OP35: Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE studyECCO’23 CopenhagenYear: 2023
Authors: FeaganSenior Scientific Officer, B.G.(1)*;Matsuoka, K.(2);Rogler, G.(3);Faes, M.(4);Oortwijn, A.(5);de Haas, A.(6);Rudolph, C.(5);Peyrin-Biroulet, L.(7);
(1)Alimentiv Inc., Division of Gastroenterology, London, Canada;(2)Toho University Sakura Medical Center, Department of Gastroenterology and Hepatology, Chiba, Japan;(3)University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Sweden;(4)Galapagos NV, Biostatistics Department, Mechelen, Belgium;(5)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(6)Galapagos NV, Clinical Development Department, Leiden, The Netherlands;(7)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;
OP36: Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD studyECCO’23 CopenhagenYear: 2023
Authors: Bokemeyer, B.(1,2,3)*;Plachta-Danielzik, S.(3);Deppe, H.(4);Mohl, W.(5);Teich, N.(6);Hoffstadt, M.(7);Schweitzer, A.(8);von der Ohe, M.(9);Gauss, A.(10);Atreya, R.(11);Krause, T.(12);Blumenstein, I.(13);Fajardo Salmon, S.(3);Hartmann, P.(4);Gilman, E.(3);Schreiber, S.(3,14);
(1)Prof. Dr. Bernd Bokemeyer, Interdisciplinary Crohn Colitis Centre Minden, Minden, Germany;(2)University Hospital Schleswig-Holstein- Campus Kiel, Clinic for General Internal Medicine I, Kiel, Germany;(3)Competence Network IBD, Study Department, Kiel, Germany;(4)Gastroenterology Practice Minden, Gastroenterology, Minden, Germany;(5)Centre for Gastroenterology Saar MVZ, Gastroenterology, Saarbrücken, Germany;(6)Gastroenterology Practice Leipzig, Gastroenterology, Leipzig, Germany;(7)Gastroenterology Practice Iserlohn, Gastroenterology, Iserlohn, Germany;(8)Gastroenterology Practice Münster, Gastroenterology, Münster, Germany;(9)Gastroenterology Practice Herne, Gastroenterology, Herne, Germany;(10)University Hospital Heidelberg, Department Internal Medicine IV - Gastroenterology Clinic, Heidelberg, Germany;(11)Friedrich-Alexander-University Erlangen-Nürnberg, Medical Clinic 1, Erlangen, Germany;(12)Gastroenterology Practice Kassel, Gastroenterology, Kassel, Germany;(13)Johann Wolfgang Goethe University Clinic Frankfurt, Department of Gastroenterology and Clinical Nutrition, Frankfurt, Germany;(14)University Hospital Schleswig-Holstein Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;
OP37: Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)ECCO’23 CopenhagenYear: 2023
Authors: Chaparro, M.(1)*;García Donday, M.(1);Riestra, S.(2);Lucendo, A.J.(3);Benítez, J.M.(4);Navarro-Llavat, M.(5);Barrio, J.(6);Morales-Alvarado, V.J.(7);Rivero, M.(8);Busquets, D.(9);Leo Carnerero, E.(10);Merino Ochoa, O.(11);Nantes Castillejo, O.(12);Navarro, P.(13);Van Domselaar, M.(14);Gutiérrez Casbas, A.(15);Alonso-Abreu, I.(16);Mejuto, R.(17);Fernández Salazar, L.(18);Iborra, M.(19); Martín-Arranz, M.D.(20); Pineda, J.R.(21); Sampedro, M.J.(22);Serra Nilsson, K.(23);Bouhmidi Assakali, A.(24);Batista, L.(25);Muñoz Villafranca, C.(26);Rodríguez-Lago, I.(27); Ceballos Santos, D.S.(28);Guerra, I.(29);Mañosa, M.(30);Marín Jimenez, I.(31); Vera Mendoza, I.(32);Barreiro-de Acosta, M.(17);Domènech, E.(30);Esteve, M.(25);García-Sánchez, V.(4);Nos, P.(19);Panés, J.(33);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- IIS-Princesa- Universidad Autónoma de Madrid UAM- and CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(3)Hospital General de Tomelloso- CIBERehd and Instituto de Investigación Sanitaria de Castilla-La Mancha IDISCAM, Gastroenterology Unit, Tomelloso, Spain;(4)Hospital universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(5)Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology Unit, Barcelona, Spain;(6)Hospital Universitario Río Hortega- Gerencia Regional de Salud de Castilla y León SACYL, Gastroenterology Unit, Valladolid, Spain;(7)Hospital General de Granollers, Gastroenterology Unit, Granollers, Spain;(8)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain;(9)Hospital Universitari Dr. Josep Trueta, Gastroenterology Unit, Girona, Spain;(10)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(11)Hospital Universitario de Cruces, Gastroenterology Unit, Baracaldo, Spain;(12)Hospital Universitario de Navarra, Gastroenterology Unit, Pamplona, Spain;(13)Hospital Clínico Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(14)Hospital Universitario de Torrejón and Universidad Francisco de Vitoria, Gastroenterology Unit, Madrid, Spain;(15)Hospital General Universitario Dr Balmis- ISABIAL and CIBERehd, Gastroenterology Unit, Alicante, Spain;(16)Hospital Universitario de Canarias, Gastroenterology Unit, Santa Cruz de Tenerife, Spain;(17)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(18)Hospital Clínico Universitario de Valladolid and Universidad de Valladolid, Gastroenterology Unit, Valladolid, Spain;(19)Hospital Universitari y Politecnic La Fe, Gastroenterology Unit, Valencia, Spain;(20)Hospital Universitario La Paz- Facultad de Medicina- Universidad Autónoma de Madrid and Instituto de Investigación Hospital universitario La Paz IdiPAZ, Gastroenterology Unit, Madrid, Spain;(21)Xerencia Xestión Integrada de Vigo- SERGAS- Research Group In Digestive Diseases- Galicia Sur Health Research Institute- SERGAS-UVIGO, Gastroenterology Unit, Vigo, Spain;(22)Hospital de Mataró, Gastroenterology Unit, Barcelona, Spain;(23)Hospital Universitari de Bellvitge, Gastroenterology Unit, L'Hospitalet de Llobregat, Spain;(24)Hospital de Santa Bárbara, Gastroenterology Unit, Puertollano, Spain;(25)Hospital Universitari Mutua Terrassa and CIBEREHD, Gastroenterology Unit, Barcelona, Spain;(26)Hospital Universitario de Basurto, Gastroenterology Unit, Bilbao, Spain;(27)Hospital Universitario de Galdakao and Instituto de Investigación Sanitaria Biocruces de Bizkaia, Gastroenterology Unit, Galdakao, Spain;(28)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain;(29)Hospital Universitario de Fuenlabrada and Instituto de Investigación Hospital Universitario La Paz IdiPAZ, Gastroenterology Unit, Madrid, Spain;(30)Hospital Universitari Germans Trias i Pujol and CIBEREHD, Gastroenterology Unit, Badalona, Spain;(31)Hospital Gregorio Marañón- Instituto de Investigación Sanitaria Gregorio Marañón IiSGM- Facultad de Medicina- Universidad Complutense, Gastroenterology Unit, Madrid, Spain;(32)Hospital Universitario Puerta de Hierro, Gastroenterology Unit, Majadahonda, Spain;(33)Hospital Clinic y Provincial, Gastroenterology Unit, Barcelona, Spain;on behalf of the EXIT Study group of GETECCU
OP38: Modulation of the septin cytoskeleton ameliorates intestinal fibrogenesisECCO’23 CopenhagenYear: 2023
Authors: Naydenov, N.(1);Le, T.H.N.(1);Lechuga Villarauz, S.(1);Elias, M.(1);West, G.(1);Czarnecki, D.(1);Plesec, T.(1);Ivanov, A.(1);Rieder, F.(2)*;
(1)Cleveland Clinic, Inflammation and Immunity, Cleveland, United States;(2)Cleveland Clinic, Department of Gastroenterology- Hepatology and Nutrition, Cleveland, United States;
OP39: Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UCECCO’23 CopenhagenYear: 2023
Authors: Ghosh, S.(1)*;Feagan, B.(2);Ott, E.(3);Gasink, C.(3);Marano, C.(4);Miao, Y.(4);Sandborn, W.(5);Danese, S.(6);Abreu, M.(7);Sands, B.(8);
(1)University College Cork, College of Medicine and Health, Cork, Ireland;(2)Western University and Alimentiv Inc., Gastroenterology, London, Canada;(3)Janssen, Scientific Affairs, Horsham, United States;(4)Janssen, Research & Development, Spring House, United States;(5)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(6)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(7)University of Miami, Miller School of Medicine, Miami, United States;(8)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
OP40: PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study ResultsECCO’23 CopenhagenYear: 2023
Authors: B. Sands*(1), L. Peyrin-Biroulet(2), S. Danese(3), D.T. Rubin(4), S. Vermeire(5), O. Laurent(6), A. Luo(6), D. Nguyen(6), JD. Lu(6),A. Wiechowska-Kozlowska(7), J. Leszczyszyn(8), R. Kempinski(9), J. Kierkus(10), C. Ma(11), T. Ritter*(12), B.G. Feagan(13), S. Targan*(14)
(1)Icahn School of Medicine at Mount Sinai, New York, New York, USA, (2)Last Inserm U954 and CHU de Nancy, Lorraine University, Nancy, France, (3)Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, (4)University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA, (5)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, (6)Prometheus Biosciences, Inc., San Diego, CA, USA, (7)Endoscopy Unit, SONOMED Medical Center, Szczecin, Poland, (8)Department of Gastroenterology, Melita Medical, Wroclaw, Poland, (9)Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland, (10)Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland, (11)Alimentiv Inc., London, ON, Canada Division of Gastroenterology & Hepatology, Department of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, (12)GI Alliance, Southlake, Texas, USA, (13)Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada, (14)Division of Gastroenterology and Hepatology, Center for Inflammatory Bowel Diseases, Cedars-Sinai Medical Center, Los Angeles, CA,USA
P001: Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.ECCO’23 CopenhagenYear: 2023
Authors: Santo, J.(1)*;Gineste, P.(1);Scherrer, D.(2);Nitcheu, J.(1);Ehrlich, H.(3);Sands, B.E.(4);Vermeire, S.(5);
(1)Abivax, Clinical Operations, Paris, France;(2)Abivax, Research and Development, Paris, France;(3)Abivax, Chief Executive Officer, Paris, France;(4)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(5)UZ Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
P002: Exclusive Enteral Nutrition, the gut microbiome and corticosteroid response in patients with acute severe colitisECCO’23 CopenhagenYear: 2023
Authors: Bajaj, A.(1)*;Markandey, M.(1);Vuyyuru, S.(1);Mohta, S.(1);Singh, M.(1);Verma, M.(1);Kumar, S.(1);Kante, B.(1);Kumar, P.(1);Makharia, G.(1);Kedia, S.(1);Travis, S.(2);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(2)University of Oxford, The Kennedy Institute and Translational Gastroenterology Unit, Oxford OX2 7FY, United Kingdom;
P003: MicroRNAs as biomarkers in Inflammatory Bowel Disease unclassified (IBDU) patient samples may predict the development from IBDU to Crohn's Disease or Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Pallikkunnath James, J.(1)*;Riis, L.B.(1,2);Malham, M.(3,4);Høgdall, E.(1,2);Langholz, E.(2,5);Nielsen, B.S.(6);
(1)Herlev University Hospital, Department of Pathology, Herlev, Denmark;(2)University of Copenhagen, Institute for Clinical Medicine, Copenhagen, Denmark;(3)Copenhagen University Hospital - Amager and Hvidovre, The Pediatric Department, Hvidovre, Denmark;(4)University of Copenhagen, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults- Hvidovre Hospital, Hvidovre, Denmark;(5)Herlev University Hospital, Department of Gasteroenterology, Herlev, Denmark;(6)Bioneer A/S, Molecular Histology, Hørsholm, Denmark;
P004: Untargeted serum metabolome shows Crohn Disease (CD) associated signature, signals that correlate with disease activity and CRP, and signals that may precede disease flareECCO’23 CopenhagenYear: 2023
Authors: Levhar, N.(1)*;Hadar, R.(1);Braun, T.(1);Efroni, G.(1);Abramovich, I.(2);Gottlieb, E.(2);Granot, M.(1);Sandra, N.(3);Selinger, L.(3);Picard, O.(3);Yavzori, M.(3);Lahat, A.(3);Eliakim, R.(3);Weiss, B.(1);Kopylov, U.(3);Ben-Horin, S.(3);Amir, A.(1);Haberman Ziv, Y.(1);
(1)Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel;(2)Technion Institute, The Ruth and Bruce Rappaport- Faculty of Medicine, Haifa, Israel;(3)Sheba Medical Center, Gastroenterology, Ramat Gan, Israel;
P005: Molecular-based classification of ulcerative colitis and its dynamicECCO’23 CopenhagenYear: 2023
Authors: Seyed Tabib, N.S.(1)*;Verstockt, S.(1);Verstockt, B.(1,2);Ferrante, M.(1,2);Sabino, J.(1,2);Vermeire, S.(1,2);
(1)KU Leuven, Department of Clinical and Experimental Medicine CHROMETA- Translational Research in GastroIntestinal Disorders TARGID, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P006: Engineered propionate-producing bacteria attenuates murine colitis by modulating the immune function of resident macrophages via histone deacetylaseECCO’23 CopenhagenYear: 2023
Authors: Feng, Z.(1)*;Wang, X.(1);Kang, G.(2);Zhao, J.(1);Ye, Y.(1);Liu, L.(1);Huang, H.(2);Cao, X.(1);
(1)Tianjin Medical University General Hospital, Department of Gastroenterology and Hepatology, Tianjin, China;(2)Tianjin University, Department of Biochemical Engineering- School of Chemical Engineering and Technology, Tianjin, China;
P007: Paradoxical effects of high and low emulsifier diets on intestinal permeability in unstressed and stressed states in healthy human adults: a pilot randomised controlled feeding trial.ECCO’23 CopenhagenYear: 2023
Authors: Fitzpatrick, J.(1)*;Gibson, P.R.(1);Taylor, K.M.(2);Halmos, E.P.(1);
(1)Monash University, Department of Gastroenterology, Melbourne, Australia;(2)Alfred Health, Department of Gastroenterology, Melbourne, Australia;
P008: Fibrostricturing Crohn's disease is characterised by an imbalance in active eosinophils, Th1, Th2 and regulatory T cellsECCO’23 CopenhagenYear: 2023
Authors: Jacobs, I.(1)*;Ke, B.J.(2);Cremer, J.(1,2);D'Hoore, A.(3);Bislenghi, G.(3);Matteoli, G.(2);De Hertogh, G.(4);Sabino, J.(2,3);Ferrante, M.(2,3);Vermeire, S.(2,3);Breynaert, C.(1,5);Vanuytsel, T.(2,3);Verstockt, B.(2,3);
(1)KU Leuven, Department of Microbiology- Immunology and transplantation, Leuven, Belgium;(2)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)KU Leuven, Department of Imaging and Pathology, Leuven, Belgium;(5)University Hospitals Leuven, Department of General Internal Medicine, Leuven, Belgium;
P009: IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cellsECCO’23 CopenhagenYear: 2023
Authors: Ullrich, K.(1)*;Derdau, J.(1);Baltes, C.(2);Rosso, G.(3);Uderhardt, S.(4);Schulze, L.L.(1);Liu, L.J.(1);Dedden, M.(1);Spocinska, M.(1);Kainka, L.(2);Kubánková, M.(3);Müller, T.M.(1);Schmidt, N.M.(1);Becker, E.(1);Atreya, I.(1);Neurath-Finotto, S.(5);Prots, I.(6);Weigmann, B.(1);López-Posadas, R.(1);Atreya, R.(1);Ekici, A.B.(7);Lautenschläger, F.(8);Guck, J.(3);Neurath, M.F.(1);Zundler, S.(1);
(1)University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany;(2)Saarland University, Experimental Physics, Saarbrücken, Germany;(3)Max Planck Institute for the Science of Light, Max-Planck-Zentrum für Physik und Medizin, Erlangen, Germany;(4)University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Medicine 3, Erlangen, Germany;(5)University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Molecular Pneumology, Erlangen, Germany;(6)University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Stem Cell Biology, Erlangen, Germany;(7)University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Human Genetics, Erlangen, Germany;(8)Saarland University, Experimental Physics- Center for Biophysics, Saarbrücken, Germany;
